PURPOSE
To educate, train and equip students from a chemistry, pharmacy or related background to enter employment as radiopharmaceutical scientists in a PET radiochemistry centre (cyclotron unit) or in a conventional radiopharmacy, to provide diagnostic and therapeutic radiopharmaceuticals to nuclear medicine centres or specialised commercial centres, or to study for PhD in this field.
DESCRIPTION
The MSc in Radiopharmaceutics & PET Radiochemistry at King's College London is unique, not only in the UK but worldwide. Radiopharmaceutics is a growing international industry facing a major skills shortage - graduates from this programme are in demand - whether in hospitals, preparing radiopharmaceuticals for cancer patients, in research in universities or industry or in the drug industry which is increasingly using PET (Positron Electron Tomography) as a major drug development tool.
The programme provides opportunities for students to develop their knowledge, understanding and skills in the principles and practice of radiopharmaceutical science; manufacturing and quality assurance of radiopharmaceuticals; appreciation of the design and operation of accelerator machines including cyclotrons; synthesis of radiopharmaceuticals from cyclotron-produced radionuclides; application of radiopharmaceuticals in biomedical research and clinical nuclear medicine.
KEY FACTS
Programme leader/s
Professor Philip Blower
Awarding institution
King's College London
Pathways
Two paths of study are offered: PET Radiochemistry (modules 1, 2, 3a, 4a and 5), suitable for those interested in a research career in the field or work in a PET radiochemistry centre; and Radiopharmaceutical Science (modules 1,2,3b, 4b and 5) to suit those interested in a career in hospital radiopharmacy. Certificate and diploma pathways are available.
Credit value (UK/ECTS equivalent)
UK 180/ECTS 90
Duration
One year FT, two years PT, September to September.
Location
St Thomas' and Waterloo Campuses. Research projects and work placements may be at other locations.
Student destinations
Expected destinations are the NHS and commercial nuclear medicine services, the pharmaceutical industry or PhD research.
Year of entry 2012
Offered by